- Home
- DRTS vs IKT Comparison
DRTS vs IKT Comparison
Compare DRTS & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRTS
- IKT
- Stock Information
- Founded
- DRTS 2015
- IKT 2008
- Country
- DRTS Israel
- IKT United States
- Employees
- DRTS N/A
- IKT N/A
- Industry
- DRTS Medical/Dental Instruments
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- DRTS Health Care
- IKT Health Care
- Exchange
- DRTS Nasdaq
- IKT Nasdaq
- Market Cap
- DRTS 158.4M
- IKT 159.2M
- IPO Year
- DRTS N/A
- IKT 2020
- Fundamental
- Price
- DRTS $2.20
- IKT $2.35
- Analyst Decision
- DRTS Strong Buy
- IKT Strong Buy
- Analyst Count
- DRTS 3
- IKT 2
- Target Price
- DRTS $8.00
- IKT $6.50
- AVG Volume (30 Days)
- DRTS 23.4K
- IKT 377.6K
- Earning Date
- DRTS 11-22-2024
- IKT 11-19-2024
- Dividend Yield
- DRTS N/A
- IKT N/A
- EPS Growth
- DRTS N/A
- IKT N/A
- EPS
- DRTS N/A
- IKT N/A
- Revenue
- DRTS N/A
- IKT $79,570.00
- Revenue This Year
- DRTS N/A
- IKT N/A
- Revenue Next Year
- DRTS N/A
- IKT N/A
- P/E Ratio
- DRTS N/A
- IKT N/A
- Revenue Growth
- DRTS N/A
- IKT N/A
- 52 Week Low
- DRTS $1.75
- IKT $0.80
- 52 Week High
- DRTS $3.40
- IKT $3.82
- Technical
- Relative Strength Index (RSI)
- DRTS 44.90
- IKT 50.22
- Support Level
- DRTS $2.20
- IKT $2.29
- Resistance Level
- DRTS $2.30
- IKT $3.69
- Average True Range (ATR)
- DRTS 0.08
- IKT 0.34
- MACD
- DRTS -0.00
- IKT -0.06
- Stochastic Oscillator
- DRTS 22.22
- IKT 4.29
About DRTS Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. The Alpha CaRT technology of the company utilizes the therapeutic properties of alpha particles aiming to overcome, and harness for benefit for alpha radiation's range. The company derives maximum revenue from Israel.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.